Gliclazide Reduces MKC Intestinal Transport in Healthy but Not Diabetic Rats

Overview

Journal Eur J Drug Metab Pharmacokinet

Date 2009 May 26

PMID 19462928

Citations 18

Authors

Hani Al-Salami

Grant Butt

Ian Tucker

Paul J Fawcett

Svetlana Golocorbin-Kon

Ivan Mikov

Momir Mikov

Affiliations

Soon will be listed here.

Abstract

The aim is to investigate the influence of the antidiabetic drug gliclazide on the ileal permeation of the semisynthetic bile acid, MKC, in tissues from healthy and diabetic rats. Sixteen Wistar rats (350 +/- 50 g) were randomly allocated into four groups (4 rats per group, 8 chambers per rat, i.e., n=32) two of which were made diabetic (given alloxan i.v. 30 mg/kg). Group 1 was used to measure the permeation of MKC (50 microg/ml) alone (control) while group 2 to measure MKC permeation in the presence of gliclazide (200 microg/ml). The diabetic groups 3 (gliclazide) and 4 (MKC+gliclazide) were treated in the same way. Rats were sacrificed and tissues were mounted into the Ussing chamber for the measurement of MKC mucosal to serosal (absorptive) and serosal to mucosal (secretory) fluxes. In healthy tissues, gliclazide reduced MKC absorptive flux (p < 0.01) and increased its secretory flux (p < 0.01). In diabetic tissues, gliclazide had no effect on either the absorptive or the secretory fluxes of MKC. The lack of effect of gliclazide on MKC permeation in diabetic tissues suggests the absence or suppressed drug transporters. Furthermore, gliclazide inhibition of MKC absorptive flux and induction of MKC secretory flux in healthy tissues may result from the selective inhibition of an efflux drug transporter.

Citing Articles

Taurine Grafted Micro-Implants Improved Functions without Direct Dependency between Interleukin-6 and the Bile Acid Lithocholic Acid in Plasma.

Mooranian A, Ionescu C, Wagle S, Kovacevic B, Walker D, Jones M Biomedicines. 2022; 10(1).

PMID: 35052790 PMC: 8772949. DOI: 10.3390/biomedicines10010111.

Chenodeoxycholic Acid Pharmacology in Biotechnology and Transplantable Pharmaceutical Applications for Tissue Delivery: An Acute Preclinical Study.

Mooranian A, Ionescu C, Wagle S, Kovacevic B, Walker D, Jones M Cells. 2021; 10(9).

PMID: 34572086 PMC: 8472107. DOI: 10.3390/cells10092437.

Pharmacological and Biological Study of Microencapsulated Probucol-Secondary Bile Acid in a Diseased Mouse Model.

Wagle S, Kovacevic B, Ionescu C, Walker D, Jones M, Carey L Pharmaceutics. 2021; 13(8).

PMID: 34452184 PMC: 8400495. DOI: 10.3390/pharmaceutics13081223.

Pharmacological and Advanced Cell Respiration Effects, Enhanced by Toxic Human-Bile Nano-Pharmaceuticals of Probucol Cell-Targeting Formulations.

Wagle S, Kovacevic B, Walker D, Ionescu C, Jones M, Stojanovic G Pharmaceutics. 2020; 12(8).

PMID: 32751051 PMC: 7463437. DOI: 10.3390/pharmaceutics12080708.

Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study.

Mooranian A, Wagle S, Kovacevic B, Takechi R, Mamo J, Lam V Sci Rep. 2020; 10(1):106.

PMID: 31919411 PMC: 6952395. DOI: 10.1038/s41598-019-53999-1.

References

Mikov M, Boni N, Al-Salami H, Kuhajda K, Kevresan S, Golocorbin-Kon S . Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3alpha,7alpha-dihydroxy-12-oxo-5beta-cholanate, in healthy and diabetic rats. Eur J Drug Metab Pharmacokinet. 2007; 32(1):7-12. DOI: 10.1007/BF03190984. View

Houten S, Watanabe M, Auwerx J . Endocrine functions of bile acids. EMBO J. 2006; 25(7):1419-25. PMC: 1440314. DOI: 10.1038/sj.emboj.7601049. View

Tsiani E, Ramlal T, Leiter L, Klip A, Fantus I . Stimulation of glucose uptake and increased plasma membrane content of glucose transporters in L6 skeletal muscle cells by the sulfonylureas gliclazide and glyburide. Endocrinology. 1995; 136(6):2505-12. DOI: 10.1210/endo.136.6.7750472. View

Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen L . Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest. 1998; 101(7):1310-9. PMC: 508708. DOI: 10.1172/JCI119886. View

Noda Y, Mori A, Packer L . Gliclazide scavenges hydroxyl, superoxide and nitric oxide radicals: an ESR study. Res Commun Mol Pathol Pharmacol. 1997; 96(2):115-24. View

Garcia-Bournissen F, Feig D, Koren G . Maternal-fetal transport of hypoglycaemic drugs. Clin Pharmacokinet. 2003; 42(4):303-13. DOI: 10.2165/00003088-200342040-00001. View

Zollner G, Fickert P, Fuchsbichler A, Silbert D, Wagner M, Arbeiter S . Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol. 2003; 39(4):480-8. DOI: 10.1016/s0168-8278(03)00228-9. View

Zollner G, Marschall H, Wagner M, Trauner M . Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm. 2006; 3(3):231-51. DOI: 10.1021/mp060010s. View

Maher S, Feighery L, Brayden D, McClean S . Melittin as a permeability enhancer II: in vitro investigations in human mucus secreting intestinal monolayers and rat colonic mucosae. Pharm Res. 2007; 24(7):1346-56. DOI: 10.1007/s11095-007-9246-z. View

10.

Stetinova V, Kvetina J, Pastera J, Polaskova A, Prazakova M . Gliclazide: pharmacokinetic-pharmacodynamic relationships in rats. Biopharm Drug Dispos. 2007; 28(5):241-8. DOI: 10.1002/bdd.550. View

11.

Rendell M . The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs. 2004; 64(12):1339-58. DOI: 10.2165/00003495-200464120-00006. View

12.

Fromm M, Kauffmann H, Fritz P, Burk O, Kroemer H, Warzok R . The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol. 2000; 157(5):1575-80. PMC: 1885746. DOI: 10.1016/S0002-9440(10)64794-3. View

13.

Zelcer N, Saeki T, Bot I, Kuil A, Borst P . Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter. Biochem J. 2002; 369(Pt 1):23-30. PMC: 1223054. DOI: 10.1042/BJ20021081. View

14.

St-Pierre M, Kullak-Ublick G, Hagenbuch B, Meier P . Transport of bile acids in hepatic and non-hepatic tissues. J Exp Biol. 2001; 204(Pt 10):1673-86. DOI: 10.1242/jeb.204.10.1673. View

15.

Faure P, Rossini E, Wiernsperger N, Richard M, Favier A, Halimi S . An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. Diabetes. 1999; 48(2):353-7. DOI: 10.2337/diabetes.48.2.353. View

16.

Lucas M . Amendments to the theory underlying Ussing chamber data of chloride ion secretion after bacterial enterotoxin exposure. J Theor Biol. 2005; 234(1):21-37. DOI: 10.1016/j.jtbi.2004.11.005. View

17.

Boisset M, Botham R, Haegele K, Lenfant B, Pachot J . Absorption of angiotensin II antagonists in Ussing chambers, Caco-2, perfused jejunum loop and in vivo: importance of drug ionisation in the in vitro prediction of in vivo absorption. Eur J Pharm Sci. 2000; 10(3):215-24. DOI: 10.1016/s0928-0987(00)00073-7. View

18.

Butt A, Mathieson S, McLeod B . Electrogenic ion transport in the intestine of the Australian common brushtail possum, Trichosurus vulpecula: indications of novel transport patterns in a marsupial. J Comp Physiol B. 2002; 172(6):495-502. DOI: 10.1007/s00360-002-0275-y. View

19.

Ballatori N, Christian W, Lee J, Dawson P, Soroka C, Boyer J . OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology. 2005; 42(6):1270-9. DOI: 10.1002/hep.20961. View

20.

Mikov M, Al-Salami H, Golocorbin-Kon S, Skrbic R, Raskovic A, Fawcett J . The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur J Drug Metab Pharmacokinet. 2008; 33(3):137-42. DOI: 10.1007/BF03191110. View